

of the MPEP specifically states:


Where, however, *the classification is the same and the field of search is the same* and there is no clear indication of separate future classification and field of search, *no reasons exist for dividing among related inventions.*

Thus, Applicants submit that restriction between Groups I and V should not be required, and respectfully request that examination of both groups in the instant application.

The Examiner has also required an election of a single species. It is Applicants' understanding that this election is being made to aid the Examiner in conducting a search and examination of the claimed subject matter, and is not to be construed as limiting the scope of Applicants' claims. It is also Applicants' understanding that if the elected subject matter is found to be allowable over the prior art, the search and examination will be expanded to cover other species, until it includes the full scope of the generic claims included in the elected group. Applicants hereby elect a species of Claim 19, wherein the radiolabeled pharmaceutical agent of formula (II) is the  $^{90}\text{Y}$  complex of Compound A, as described on page 68 *et seq.* of Applicants' specification, and the compound of formula (I) is trihydroxybenzoic acid. For Claim 38, the elected second stabilizer is gentisic acid. Applicants list claims 19-22, 30-33, and 38-39, as readable on the elected species.

If the Examiner has any questions, the Examiner is invited to call the undersigned.

Date: April 8, 2003

  
\_\_\_\_\_  
Brian J. Hubbard  
Registration No. 45,873

Woodcock Washburn LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439